- Home
- FRES vs GNLX Comparison
FRES vs GNLX Comparison
Compare FRES & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRES
- GNLX
- Stock Information
- Founded
- FRES 2010
- GNLX 2001
- Country
- FRES United States
- GNLX United States
- Employees
- FRES N/A
- GNLX N/A
- Industry
- FRES Medical Specialities
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- FRES Health Care
- GNLX Health Care
- Exchange
- FRES Nasdaq
- GNLX Nasdaq
- Market Cap
- FRES N/A
- GNLX 103.6M
- IPO Year
- FRES 2020
- GNLX 2023
- Fundamental
- Price
- FRES $1.12
- GNLX $2.27
- Analyst Decision
- FRES
- GNLX Strong Buy
- Analyst Count
- FRES 0
- GNLX 4
- Target Price
- FRES N/A
- GNLX $18.25
- AVG Volume (30 Days)
- FRES 13.5K
- GNLX 142.7K
- Earning Date
- FRES 12-31-2024
- GNLX 11-14-2024
- Dividend Yield
- FRES N/A
- GNLX N/A
- EPS Growth
- FRES N/A
- GNLX N/A
- EPS
- FRES N/A
- GNLX N/A
- Revenue
- FRES $2,341,326.00
- GNLX $8,000.00
- Revenue This Year
- FRES N/A
- GNLX N/A
- Revenue Next Year
- FRES N/A
- GNLX N/A
- P/E Ratio
- FRES N/A
- GNLX N/A
- Revenue Growth
- FRES 94.50
- GNLX N/A
- 52 Week Low
- FRES $0.85
- GNLX $1.60
- 52 Week High
- FRES $9.03
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- FRES 42.61
- GNLX 38.68
- Support Level
- FRES $1.00
- GNLX $2.13
- Resistance Level
- FRES $1.40
- GNLX $2.80
- Average True Range (ATR)
- FRES 0.22
- GNLX 0.20
- MACD
- FRES -0.01
- GNLX -0.04
- Stochastic Oscillator
- FRES 23.55
- GNLX 14.21
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.